AN FRANCISCO — The drug industry’s top lobbying group has a plan for the $100 million in extra dues it will soon be collecting from members: a stepped-up ad campaign highlighting just how hard it is to invent new treatments.

Pharmaceutical Research and Manufacturers of America, which just raised its annual fees by 50 percent, is hoping to counter the industry’s worsening reputation, brought on by increased public scrutiny of escalating drug prices. One facet of that effort will be a national ad campaign, PhRMA President and CEO Stephen Ubl said Monday at the J.P. Morgan Healthcare Conference.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.